First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.

about

First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.

Item

http://www.wikidata.org/entity/Q36354843

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

First-in-man experience of sel ...... ropopliteal occlusive disease.

@ast

First-in-man experience of sel ...... ropopliteal occlusive disease.

@en

type

Item

label

First-in-man experience of sel ...... ropopliteal occlusive disease.

@ast

First-in-man experience of sel ...... ropopliteal occlusive disease.

@en

prefLabel

First-in-man experience of sel ...... ropopliteal occlusive disease.

@ast

First-in-man experience of sel ...... ropopliteal occlusive disease.

@en

P1476

First-in-man experience of sel ...... oropopliteal occlusive disease

@en

P2093

Ali Daneshmand

http://www.w3.org/2001/XMLSchema#string

Kalpa Perera

http://www.w3.org/2001/XMLSchema#string

Rhys Daniel

http://www.w3.org/2001/XMLSchema#string

Sally A Burrows

http://www.w3.org/2001/XMLSchema#string

Shannon D Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

An update on endovascular therapy of the lower extremities.

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.

Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis.

Drug-coated balloons for the prevention of vascular restenosis.

Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials.

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).

Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.

4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial.

Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial.

Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial.

P304

3-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1708538117705805

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bibombe P Mwipatayi

Jackie Wong

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28436316

http://www.w3.org/2001/XMLSchema#string

P932

5808812

http://www.w3.org/2001/XMLSchema#string